Kahr Medical Ltd.
- Biotech or pharma, therapeutic R&D
KAHR Medical is developing DSP107 to treat the two leading causes of death from cancer, Colorectal and Lung Cancer. DSP107 is a bispecific, bifunctional t cell enhancer that demonstrated improved survival, responses rates, and disease control rates in third line MSS colorectal cancer in its phase 1/2a trial. KAHR is seeking to raise capital to fund a randomized controlled phase 2b trial.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}